Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia.

Abstract

BACKGROUND:

Severe hypercholesterolemia is a major risk factor of death in patients with coronary heart disease. New adjunctive drug therapies (proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors) have gained approval in Europe and the USA.

OBJECTIVE:

In this empirical study, we documented preferences regarding adjuvant drug therapy in apheresis-treated patients with severe familial hypercholesterolemia.

METHODS:

We conducted a systematic literature search to identify patient-relevant outcomes in patients with severe hypercholesterolemia currently undergoing apheresis. Data were used to generate a semi-structured qualitative interview that enabled seven patient-relevant characteristics with three levels each to be identified. For the discrete choice experiment, an experimental design (7 × 3) was generated using NGene Software that consisted of 96 choices divided into eight blocks. The survey was conducted between November 2015 and April 2016 using computer-assisted personal interviews.

RESULTS:

The survey was completed by 348 patients (64.9% male). The random parameter logit estimation showed predominance for the attribute 'reduction of LDL-C (low-density lipoprotein cholesterol) level'. 'Risk of myopathy' and 'frequency of apheresis' dominated next. Within the random parameter logit estimation, all coefficients were significant (P ≤ 0.01). The latent class analysis identified three patient groups. The first group (126 patients) found 'reduction of LDL-C level in blood' to be most important. This group focused solely on this treatment outcome independently of apheresis frequency or additional injections. The second group (106 patients) focused on three attributes: 'frequency of apheresis', 'risk of myopathy', and 'reduction of LDL-C level in blood'. Respondents clearly considered a high frequency of apheresis to have a negative impact. The third group (116 patients) demonstrated the highest preference for apheresis. These patients have adjusted to apheresis for > 10 years.

CONCLUSION:

Regarding patient preference, clinical efficacy seems to dominate. Hence, 'reduction of LDC-C in blood' was ranked highest above patient-relevant modes of administration and adverse effects. In the patient groups identified, reduction of apheresis was important for only a subsegment (30%) of patients. Another 30% wanted effective LDL-C reduction by whatever means necessary. Most strikingly, another 30% preferred higher frequencies of apheresis.

• Authors: Axel C Mühlbacher, Andrew Sadler, Franz-Werner Dippel, Christin Juhnke
• Journal: PharmacoEconomics (Pharmacoeconomics) Vol. 36 Issue 4 Pg. 477-493 (04 2018) ISSN: 1179-2027 [Electronic] New Zealand
• PMID: 29388056 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Protease Inhibitors

Topics

• Adult
• Aged
• Aged, 80 and over
• Blood Component Removal (psychology)
• Decision Making
• Female
• Germany
• Humans
• Hyperlipoproteinemia Type II (drug therapy, psychology)
• Male
• Middle Aged
• Patient Preference (psychology)
• Protease Inhibitors (therapeutic use)